From Aspirin to Targeting KRAS: These Technologies Are Redrawing the Frontiers of Drug Discovery From aspirin to modern KRAS inhibitors,...

From Discovery to the Clinic: Drug discovery does not move forward through isolated steps. A promising biological insight must be...

Targeted protein degradation (TPD) is moving beyond traditional E3 ligases such as CRBN and VHL, with growing interest in identifying...

As pipeline molecules become increasingly complex, traditional ligand-binding assays may not always provide the level of characterization required. WuXi Biology’s...

As therapeutic modalities continue to expand beyond small molecules and monoclonal antibodies, one principle is becoming increasingly important in drug...

Matching the Right Target, Modality, and Patient: As oncology drug discovery becomes increasingly modality-rich and biologically complex, one question is...

How Integrating Chemistry and Biology Reshapes Early Drug Development: At the American Association for Cancer Research (AACR) Annual Meeting, the...